Link to this page
Biological and Environmental Research Ontology
Last uploaded:
December 23, 2022
| Id | http://purl.obolibrary.org/obo/NCIT_C80043
http://purl.obolibrary.org/obo/NCIT_C80043
|
|---|---|
| Preferred Name | Codrituzumab |
| Definitions |
A humanized monoclonal antibody directed against the cell surface oncofetal protein glypican-3 (GPC3) with potential antineoplastic activity. Anti-GPC3 monoclonal antibody GC33 binds to GPC3 and triggers a host immune response against GPC3-expressing tumor cells, which may result in tumor cell death. GPC3, a heparin sulfate proteoglycan, is frequently upregulated in hepatocellular carcinoma and mesoderm-derived organs such as the liver, lungs, and kidney.
|
| Type | http://www.w3.org/2002/07/owl#Class |
All Properties
| definition | A humanized monoclonal antibody directed against the cell surface oncofetal protein glypican-3 (GPC3) with potential antineoplastic activity. Anti-GPC3 monoclonal antibody GC33 binds to GPC3 and triggers a host immune response against GPC3-expressing tumor cells, which may result in tumor cell death. GPC3, a heparin sulfate proteoglycan, is frequently upregulated in hepatocellular carcinoma and mesoderm-derived organs such as the liver, lungs, and kidney. |
|---|---|
| prefLabel | Codrituzumab
|
| label | Codrituzumab
|
| NCI_META_CUI | CL388379
|
| PDQ_Closed_Trial_Search_ID | 614683
|
| code | C80043
|
| Has_Target | |
| prefixIRI | NCIT:C80043
|
| in_subset |
See more
See less
|
| Display_Name | Codrituzumab
|
| Preferred_Name | Codrituzumab
|
| FDA_UNII_Code | U9I0PLD4HT
|
| Contributing_Source |
CTRP
FDA
|
| Maps_To | Codrituzumab
|
| CAS_Registry | 1365267-33-9
|
| NCI_Drug_Dictionary_ID | 614683
|
| Legacy Concept Name | Codrituzumab
|
| type | |
| Is_Value_For_GDC_Property | |
| subClassOf | |
| PDQ_Open_Trial_Search_ID | 614683
|
| Semantic_Type |
Amino Acid, Peptide, or Protein
Pharmacologic Substance
Immunologic Factor
|
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |